Welcome to our dedicated page for Biostem Tech news (Ticker: BSEM), a resource for investors and traders seeking the latest updates and insights on Biostem Tech stock.
BioStem Technologies, Inc. (OTC: BSEM) generates news that reflects its role as a MedTech company focused on placental-derived allografts for advanced wound care and regenerative therapies. Coverage of BSEM often centers on clinical trial milestones, reimbursement developments, financial reporting, and operational updates related to its BioRetain®-processed product portfolio, which includes brands such as AmnioWrap2™, VENDAJE®, VENDAJE AC®, VENDAJE OPTIC®, American Amnion™, and American Amnion AC™.
Investors and healthcare professionals following BSEM news can expect updates on randomized controlled trials and other clinical studies evaluating BioRetain-preserved placental allografts in chronic wound indications like diabetic foot ulcers and venous leg ulcers. The company has reported top-line clinical results from a multicenter randomized controlled trial in non-healing diabetic foot ulcers, as well as comparative studies versus standard of care and competitor products, and these types of announcements are key components of its news flow.
Another major theme in BioStem’s news is reimbursement and policy. The company regularly comments on Centers for Medicare & Medicaid Services (CMS) rules and Local Coverage Determinations affecting skin substitutes and cellular and tissue-based products. News items have addressed the placement of VENDAJE and VENDAJE AC in a “12-Month Status Quo” category under certain LCDs, the withdrawal of specific LCDs, and the inclusion of these products on Florida Medicaid’s list of covered skin substitutes, along with coverage in multiple state Medicaid programs.
Financial and corporate developments also feature prominently. BioStem has issued press releases on quarterly financial results, restated financial statements related to the treatment of bona fide services fees in a distribution agreement, and the appointment of a new independent registered public accounting firm. Operational news has included the purchase of land in the Research Park at Florida Atlantic University in Boca Raton, Florida, for a future headquarters, as well as partnerships to serve the U.S. Department of Veterans Affairs and community initiatives supporting veterans.
By monitoring this news page, readers can follow BioStem’s clinical evidence generation, reimbursement positioning, financial reporting, and strategic initiatives as they relate to its placental-derived advanced wound care products and BioRetain processing technology.
BioStem Technologies (OTC: BSEM) announced it purchased a four-acre parcel at the Research Park at Florida Atlantic University in Boca Raton to serve as its future headquarters for administrative offices, manufacturing, and distribution.
The City approved up to $300,000 in economic incentives tied to the creation of up to 100 jobs over five years. The company has not set a timetable for relocation. BioStem highlights its FDA-registered, AATB-accredited manufacturing site in Pompano Beach and its placental-derived wound-care product portfolio, including AmnioWrap 2 and VENDAJE brands.
BioStem Technologies (OTC: BSEM) reported top-line randomized controlled trial results published in the International Journal of Tissue Repair showing BioRetain (BR-AC) produced higher lasting wound-closure rates than standard of care in hard-to-heal diabetic foot ulcers (DFUs).
Key metrics: probability of lasting closure 53% for BR-AC vs 31% for standard of care over a 12-week period; study enrolled 71 patients across 11 U.S. sites, initiated Q4 2024, with lasting closure defined as remaining closed for 4 weeks. Future publications will report secondary endpoints including time to closure, wound area/volume change, and number of BR-AC applications.
BioStem Technologies (OTC: BSEM) will release its third quarter 2025 financial results on Thursday, November 13, 2025, and will host a conference call and webcast at 4:30 PM ET.
The webcast will feature an overview of the quarter from Jason Matuszewski, CEO, and Brandon Poe, CFO. Conference ID and dial-in numbers are provided for North America and international participants, and a live webcast link is available for online attendees.
BioStem Technologies (OTC: BSEM) announced that its Audit Committee approved the appointment of KPMG LLP as its independent registered public accounting firm, ending its engagement with Marcum (now CBIZ) effective Oct 22, 2025. The company said KPMG was selected for its life sciences expertise to support BioStem's growth and planned uplist to Nasdaq following completion of full-year 2024 and 2025 audits. Management emphasized the uplisting as a priority to improve liquidity, visibility, and market valuation. The company also stated there were no disagreements with Marcum during the two most recent fiscal years and any interim period before the dismissal.
BioStem Technologies (OTC: BSEM) has expanded its partnership with the Florida Panthers as the new sponsor of the "Heroes Among Us" program for its 13th season in 2025-26. The program, which has honored over 500 military veterans since 2013, recognizes one military hero at each Panthers home game with a national anthem dedication and video tribute.
BioStem will also continue supporting the "Seats for Service" program, which has provided 125 seats to veterans since the 2024-25 season. The initiative offers veterans four game tickets, parking, and a $50 food credit at Amerant Bank Arena. This partnership aligns with BioStem's upcoming launch of their American Amnion product line for military wound care and reflects the company's commitment to veterans, exemplified by their co-founder Andrew Van Vurst, a U.S. Marine Corps veteran.
BioStem Technologies (OTC: BSEM) announced its participation in the Symposium for Advanced Wound Care (SAWC) Fall meeting in Las Vegas from September 3-6, 2025. The company is co-exhibiting with strategic partner Venture Medical, LLC to showcase their combined wound care management solutions.
The exhibition features three scientific posters highlighting BioStem's proprietary BioREtain® technology and allograft portfolio. The company's leading products, AmnioWrap2® and Vendaje AC®, are exclusively available through Venture Medical and integrated with the Venture OneView™ platform for streamlined chronic wound care management.
The event includes scheduled booth presentations on wound care topics and a sponsored breakfast symposium titled "Navigating the Future of Wound Care," focusing on clinical evidence, allograft selection, and practice management.
BioStem Technologies (OTC:BSEM), a MedTech company specializing in placental-derived biologics for advanced wound care, has announced its participation in two upcoming investor conferences in New York.
The company will participate in a fireside chat at the Morgan Stanley Global Healthcare Conference on September 8, 2025, at 3:20 PM ET, followed by a presentation at the H.C. Wainwright 27th Annual Global Investment Conference on September 9, 2025, at 11:00 AM ET. Investors can access live and archived webcasts of both presentations through BioStem's investor relations website.
BioStem Technologies (OTC: BSEM), a MedTech company specializing in placental-derived products for advanced wound care, announced a significant insider purchase by its Chairman and CEO, Jason Matuszewski.
On August 19, 2025, Matuszewski acquired 15,500 shares through two transactions: 2,500 shares at $6.28 and 13,000 shares at $6.51, totaling approximately $100,000. Following these purchases, his total ownership stands at 1,145,362 shares.
BioStem Technologies (OTC: BSEM) reported preliminary Q2 2025 financial results, marking its sixth consecutive quarter of positive adjusted EBITDA. The company generated net revenue of $49.3M, down 34% YoY, with adjusted EBITDA of $2.5M compared to $10.1M in Q2 2024. The company reported a GAAP net loss of $0.6M or ($0.03) per share.
Key developments include the appointment of Brandon Poe as CFO, completion of enrollment in a clinical trial for BioREtain® Amnion Chorion, and expansion of intellectual property with three new U.S. patent applications. The company's cash position strengthened to $30.8M, up $4.1M from Q1. BioStem continues to pursue Nasdaq uplisting and is working through historical financial statement audits.
BioStem Technologies (OTC: BSEM), a MedTech company specializing in placental-derived advanced wound care products, has appointed Brandon Poe as its new Chief Financial Officer. Poe, who has served on BioStem's Board since 2022, brings over 25 years of healthcare and life sciences experience, including senior finance roles at Midi Health, Jumpcode Genomics, and Illumina.
The appointment comes at a strategic time as BioStem pursues market expansion and Nasdaq uplisting plans. The former CFO, Michael Fortunato, will transition to the role of Chief Accounting Officer. Poe's extensive background in capital markets and operational excellence, combined with his familiarity with BioStem's business, positions him to support the company's growth initiatives and BioREtain® platform development.